BioAtla to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
BioAtla (Nasdaq: BCAB), a global clinical-stage biotechnology company, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024. BioAtla's management will provide a corporate update in a pre-recorded fireside chat format, which will be available on-demand starting Monday, September 9, at 7:00 a.m. ET.
BioAtla specializes in developing Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors. This conference participation offers an opportunity for investors and industry professionals to gain insights into BioAtla's latest developments and strategic direction in the field of oncology therapeutics.
BioAtla (Nasdaq: BCAB), una compagnia biotecnologica globale in fase clinica, ha annunciato la sua partecipazione alla 26ª Conferenza Annuale di Investimento Globale H.C. Wainwright. L'evento è programmato per 9-11 settembre 2024. La direzione di BioAtla fornirà un aggiornamento aziendale in un formato di chiacchierata pre-registrata, che sarà disponibile on-demand a partire da lunedì 9 settembre, alle 7:00 a.m. ET.
BioAtla si specializza nello sviluppo di terapeutiche anticorpali Conditionally Active Biologic (CAB) per il trattamento dei tumori solidi. Questa partecipazione alla conferenza offre un'opportunità per investitori e professionisti del settore di acquisire informazioni sugli ultimi sviluppi e sulla direzione strategica di BioAtla nel campo delle terapeutiche oncolologiche.
BioAtla (Nasdaq: BCAB), una empresa global de biotecnología en etapa clínica, ha anunciado su participación en la 26ª Conferencia Anual de Inversión Global H.C. Wainwright. El evento está programado para el 9-11 de septiembre de 2024. La dirección de BioAtla proporcionará una actualización corporativa en un formato de charla pregrabada, que estará disponible bajo demanda a partir del lunes 9 de septiembre a las 7:00 a.m. ET.
BioAtla se especializa en desarrollar terapéuticas de anticuerpos Conditionally Active Biologic (CAB) para el tratamiento de tumores sólidos. Esta participación en la conferencia ofrece una oportunidad para que inversores y profesionales de la industria obtengan información sobre los últimos desarrollos y la dirección estratégica de BioAtla en el campo de las terapias oncológicas.
BioAtla (Nasdaq: BCAB)는 글로벌 임상 단계의 생명공학 회사로서 H.C. Wainwright 제26회 연례 글로벌 투자 컨퍼런스에 참여한다고 발표했습니다. 이 행사는 2024년 9월 9-11일로 예정되어 있습니다. BioAtla 경영진은 기업 업데이트를 미리 녹화한 파이어사이드 대화 형식으로 제공할 예정이며, 이는 9월 9일 월요일 오전 7:00 ET부터 온디맨드로 제공됩니다.
BioAtla는 고형 종양 치료를 위한 조건부 활성 생물학적(CAB) 항체 치료제 개발에 전문화되어 있습니다. 이번 컨퍼런스 참여는 투자자와 산업 전문가에게 BioAtla의 최신 개발 및 종양학 치료 분야의 전략적 방향에 대한 통찰을 얻을 수 있는 기회를 제공합니다.
BioAtla (Nasdaq: BCAB), une entreprise biopharmaceutique mondiale en phase clinique, a annoncé sa participation à la 26ème Conférence Annuelle d'Investissement Mondial H.C. Wainwright. L'événement est prévu pour le 9-11 septembre 2024. La direction de BioAtla donnera une mise à jour de l'entreprise sous la forme d'une discussion devant la cheminée enregistrée à l'avance, qui sera disponible à la demande à partir de lundi 9 septembre à 7h00 ET.
BioAtla se spécialise dans le développement de thérapeutiques anticorpales Conditionally Active Biologic (CAB) pour le traitement des tumeurs solides. Cette participation à la conférence offre une occasion aux investisseurs et aux professionnels de l'industrie d'obtenir des informations sur les dernières évolutions et la direction stratégique de BioAtla dans le domaine des thérapeutiques en oncologie.
BioAtla (Nasdaq: BCAB), ein global tätiges Unternehmen der biopharmazeutischen Industrie in klinischer Phase, hat seine Teilnahme an der 26. Jährlichen Global Investment Conference von H.C. Wainwright bekannt gegeben. Die Veranstaltung ist für 9.-11. September 2024 angesetzt. Das Management von BioAtla wird ein Unternehmensupdate im Format eines vorab aufgezeichneten Fireside-Chats bereitstellen, das ab Montag, dem 9. September, um 7:00 Uhr ET auf Abruf verfügbar sein wird.
BioAtla hat sich auf die Entwicklung von Conditional Active Biologic (CAB) Antikörpertherapeutika zur Behandlung solider Tumoren spezialisiert. Diese Teilnahme an der Konferenz bietet Investoren und Fachleuten aus der Branche die Möglichkeit, Einblicke in die neuesten Entwicklungen und strategischen Ausrichtungen von BioAtla im Bereich der Onkologie-Therapeutika zu gewinnen.
- None.
- None.
SAN DIEGO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that the Company’s management will provide a corporate update at the H.C. Wainwright 26th Annual Global Investment Conference, to be held September 9-11, 2024.
Format: Fireside chat
Date/Time: Pre-recorded presentation available on-demand Monday, September 9, at 7:00 a.m. ET
Webcast Link: Click Here
About BioAtla®, Inc.
BioAtla is a global clinical-stage biotechnology company with operations in San Diego, California, and in Beijing, China through our contractual relationship with BioDuro-Sundia, a provider of preclinical development services. Utilizing its proprietary Conditionally Active Biologics (CAB) technology, BioAtla develops novel, reversibly active monoclonal and bispecific antibodies and other protein therapeutic product candidates. CAB product candidates are designed to have more selective targeting, greater efficacy with lower toxicity, and more cost-efficient and predictable manufacturing than traditional antibodies. BioAtla has extensive and worldwide patent coverage for its CAB technology and products with greater than 765 active patent matters, more than 500 of which are issued patents. Broad patent coverage in all major markets include methods of making, screening and manufacturing CAB product candidates in a wide range of formats and composition of matter coverage for specific products. BioAtla has two first-in-class CAB programs currently in Phase 2 clinical testing, mecbotamab vedotin, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and ozuriftamab vedotin, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). The Phase 2 stage CAB-CTLA-4 antibody, evalstotug, is a novel CTLA-4 inhibitor designed to reduce systemic toxicity and potentially enable safer combination therapies with checkpoint inhibitors such as anti-PD-1 antibody. The company’s first dual CAB bispecific T-cell engager antibody, BA3182, is currently in Phase 1 development. BA3182 targets EpCAM, which is highly and frequently expressed on many adenocarcinomas while engaging human CD3 expressing T cells. BioAtla has an FDA-cleared IND for its next-gen CAB-Nectin4-ADC, BA3361, the Company’s first glycoconjugate. To learn more about BioAtla, Inc. visit www.bioatla.com.
Internal Contact:
Richard Waldron
Chief Financial Officer
BioAtla, Inc.
rwaldron@bioatla.com
858.356.8945
External Contact:
Bruce Mackle
LifeSci Advisors, LLC
bmackle@lifesciadvisors.com
FAQ
When is BioAtla (BCAB) presenting at the H.C. Wainwright Global Investment Conference?
What type of therapeutics does BioAtla (BCAB) develop?
What is the format of BioAtla's (BCAB) presentation at the H.C. Wainwright conference?
When is the H.C. Wainwright 26th Annual Global Investment Conference taking place?
